Australian Study Says Most Weight-Loss Drugs Never Tested (Australia)
This article was originally published in PharmAsia News
An Australian study says the country's regulations governing complementary medicines need to be overhauled so the sale of many weight-loss drugs can be halted. The study made the recommendation as a result of an investigation of many of the products, finding they either do no work at all or were never properly tested. The researcher behind the study said the Therapeutic Goods Administration assumes the weight-loss medicines are harmless, but Dr. Ken Harvey of La Trobe University said that theory is out of date by 10 or 15 years. (Click here for more
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.